Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Selection Study of Ad2/HIF-1α/VP16 in Intermittent Claudication
2004-002508-13Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2005
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arteriosclerosis obliterans and intermittent claudication (IC) comparing Ad2/HIF-1α/VP16 with Placebo (2 arms). Primary endpoint: Safety of Ad2/HIF-1α/VP16. Started Mar 2005; status: completed.
02
Drugs
Ad2/HIF-1α/VP16
03
Conditions
arteriosclerosis obliteransintermittent claudication (IC)
Beyond the preview
Go deeper on 2004-002508-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002508-13.